Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the new world

Clinical and Vaccine Immunology

Volumn 14, Issue 9, 2007, Pages 1173-1181

  Salay, G ^a   Dorta, M L ^a,b   Santos, N M ^a   Mortara, R A ^a   Brodskyn, C ^c,d   Oliveira, C I ^c   Barbieri C L ^a   Rodrigues, M M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Universidade Federal de Gois   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; HOMOLOGUE OF RECEPTOR FOR ACTIVATED C KINASE; LEISHMANIA ELONGATION AND INITIATION FACTOR; LEISHMANIA MAJOR STRESS INDUCIBLE PROTEIN 1; PLASMID VECTOR; RECOMBINANT ANTIGEN; THIOL SPECIFIC ANTIOXIDANT; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA VECTOR; GENE EXPRESSION; GENE INSERTION; GENE ISOLATION; IMMUNIZATION; LEISHMANIA BRAZILIENSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; PROTOZOAL GENETICS; PROVOCATION; RECOMBINANT PLASMID; SKIN LEISHMANIASIS; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOASSAY; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; LIFE CYCLE STAGES; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PEPTIDE INITIATION FACTORS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, SYNTHETIC;

EID: 34948860200     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00060-07     Document Type: Article

References (36)

1. Alfieri, S. C., V. Zilberfarb, and M. Rabinovitch. 1987. Destruction of Leishmania mexicana amazonensis amastigotes by leucine methyl ester: protection by other amino acid esters. Parasitology 95:31-41.
2. Barbieri, C. L., A. I. Doine, and E. Freymuller. 1990. Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp. Parasitol. 71:218-228.
3. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical-mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
4. Boscardin, S. B., S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues. 2003. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect. Immun. 71:2744-2757.
5. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. Skeiky, and S. G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2828-2836.
6. Campos-Neto, A., R. Porrozzi, K. Greeson, R. N. Coler, J. R. Webb, Y. A. Skeiky, S. G. Reed, and G. Grimaldi, Jr. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:4103-4108.
7. CENEPI. 2007. Manual for surveillance of American integumentary leishmaniasis, 2nd ed. Brazilian Health Ministry, Brasília, Brazil. http://portal.saude.gov.br/portal/arquivos/pdf/manual_lta_2ed.pdf.
8. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:3272-3279.
9. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
10. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigen thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
11. Convit, J., M. Ulrich, C. T. Fernandez, F. J. Tapia, G. Caceres-Dittmar, M. Castes, and A. J. Rondon. 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 87:444-448.
12. Fong, D., M. Wallach, J. Keithly, P. Melera, and K. P. Chang. 1984. Differential expression of mRNAs for α- and β-tubulin during differentiation of the parasitic protozoan Leishmania mexicana. Proc. Natl. Acad. Sci. USA 78:7624-7628.
13. Grogl, M., T. N. Thomaso, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
14. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
15. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
16. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
17. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. G. Reed, R. A. Seder, and D. L. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
18. Mendez, S., Y. Belkaid, R. A. Seder, and D. L. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
19. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z. E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
20. Moura, T. R., F. O. Novais, F. Oliveira, J. Clarencio, A. Noronha, A. Barral, C. Brodskyn, and C. I. Oliveira. 2005. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect. Immun. 73:5827-5834.
21. Reed, S. G., R. N. Coler, and A. Campos-Neto. 2003. Development of a leishmaniasis vaccine: the importance of MPL. Expert. Ver. Vaccines 2:239-252.
22. + T-cell responses and protection against Leishmania major infection. J. Exp. Med. 195:1565-1573.
23. Rodrigues, M. M., M. Ribeirão, V. L. Pereira-Chioccola, L. Renia, and F. Costa. 1999. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect. Immun. 67:3855-3863.
24. Rojas, R., L. Valderrama, M. Valderrama, M. X. Varona, M. Ouellette, and N. G. Saravia. 2006. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 193:1375-1383.
25. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, New York, NY.
26. Shaw, J. J. 1999. The relationship of sand fly ecology to the transmission of leishmaniasis in South America with particular reference to Brazil, p. 503-517. In J. Burger (ed.), Memoirs on entomology, international, vol. 14. Associated Publishers, Gainesville, FL.
27. Sheffield, P., S. Garrard, and Z. Derewenda. 1999. Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein Expr. Purif. 15:34-39.
28. Skeiky, Y. A., J. A. Guderian, D. R. Benson, O. Bacelar, E. M. Carvalho, M. Kubin, R. Badaro, G. Trinchieri, and S. G. Reed. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. J. Exp. Med. 181:1527-1537.
29. Skeiky, Y. A., M. Kennedy, D. Kaufman, M. M. Borges, J. A. Guderian, J. K. Scholler, P. J. Ovendale, K. S. Pich, P. J. Morrissey, K. H. Grabstein, A. Campos-Neto, and S. G. Reed. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated cytokine profile. J. Immunol. 161:6171-6179.
30. Skeiky, Y. A., R. N. Coler, M. Brannon, E. Stromberg, K. Greenson, R. T. Crane, A. Campos-Neto, and S. G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant. Vaccine 20:3292-3303.
31. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1998. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
32. Ullman, B. 1995. Multidrug resistance and P-glycoproteins in parasitic protozoa. J. Bioenerg. Biomembr. 27:77-84.
33. Vasconcelos, J. R., S. B. Boscardin, M. I. Hiyane, S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues. 2003. A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain. Immunol. Cell Biol. 81:121-129.
34. Webb, J. R., A. Campos-Neto, Y. A. Skeiky, and S. G. Reed. 1997. Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol. Biochem. Parasitol. 89:179-193.
35. Webb, J. R., A. Campos-Neto, P. J. Ovendale, T. I. Martin, E. J. Stromberg, R. Badaro, and S. G. Reed. 1998. Human and murine immune response to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
36. Webb, J. R., D. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.